Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01335698 · ClinicalTrials.gov registry record · Phase 3
Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients
A Phase 3 study of HIV, sponsored by Bristol-Myers Squibb.
- Completed
- Registry status
- Phase 3
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT01335698 is a Phase 3 study of HIV that has completed, run by Bristol-Myers Squibb. The registered enrollment target is 160 participants, below the 439-participant average among 303 other HIV trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 11 states.
The verdict
NCT01335698, a Phase 3 study of HIV, has completed, sponsored by Bristol-Myers Squibb.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
The purpose of this study is to describe the safety, efficacy, and pharmacokinetics of a regimen of atazanavir powder boosted with ritonavir and an optimized dual nucleoside reverse transcriptase inhibitor in pediatric patients aged ≥3 months to \<11 years.
Conditions Studied
Interventions
- DRUG Ritonavir
- DRUG Atazanavir Sulphate
Study Locations (20)
Other
- Local Institution - Oaxaca City
- Local Institution - Puebla City
- Local Institution - Warsaw
- Local Institution - Bucharest
- Local Institution - Saint Petersburg
- Local Institution - Saint Petersburg
Buenos Aires
- Local Institution - Buenos Aires, Bs As
- Local Institution - Bunos Aires
Rio Grande do Sul
- Local Institution - Porto Alegre
- Local Institution - Porto Alegre
Santiago Metropolitan
- Local Institution - Santiago
- Local Institution - Santiago
Jalisco
- Local Institution - Guadalajara
- Local Institution - Guadalajara
District of Columbia
- Children'S National Medical Center - Washington D.C.
New York
- SUNY Upstate Medical University - Syracuse
Pernambuco
- Local Institution - Recife
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2011-05-27 |
| Est. Completion | 2018-01-22 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01335698
The ClinicalTrials.gov registry entry for NCT01335698 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 160 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 439-participant average among 303 other HIV trials with a reported enrollment target (64% lower). The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with HIV appearing as the primary indexed condition, and to 2 interventions - of which Ritonavir is the first listed.
NCT01335698 reports 20 study locations spanning 11 distinct geographic areas - top geographies include Other, Buenos Aires, Rio Grande do Sul.
Frequently Asked Questions
What is clinical trial NCT01335698 about?
NCT01335698 is a clinical study titled "Phase IIIB Study Evaluating the Effects of Atazanavir Powder With Ritonavir in HIV-infected Pediatric Patients". The purpose of this study is to describe the safety, efficacy, and pharmacokinetics of a regimen of atazanavir powder boosted with ritonavir and an optimized dual nucleoside reverse transcriptase inhibitor in pediatric patients aged ≥3 months to \<11 years.
What is the current status of trial NCT01335698?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 160 participants. The study started on 2011-05-27. Estimated completion is 2018-01-22.
What conditions does trial NCT01335698 study?
This clinical trial studies the following conditions: HIV.
What interventions are being tested in trial NCT01335698?
The interventions under investigation include: Ritonavir (DRUG), Atazanavir Sulphate (DRUG).
Who is sponsoring clinical trial NCT01335698?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01335698 being conducted?
This trial has 20 study locations across District of Columbia, New York, Buenos Aires, Pernambuco, Rio Grande do Sul. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HIV
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate Efficacy, Safety and Tolerability in Antiretroviral Therapy (ART)-Experienced Participants of at Least 50 Years of Age Living With Human Immunodeficiency Virus (HIV) With Virologic Suppression Who Switch to DTG/3TC FDC From BIC/FTC/TAF
ACTIVE NOT RECRUITING · Phase 3
-
Efficacy of Tenofovir Alafenamide Versus Placebo Added to a Failing Regimen Followed by Treatment With Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Plus Atazanavir in HIV-1 Positive, Antiretroviral Treatment-Experienced Adults
COMPLETED · Phase 3
-
Training Community Members to Deliver HIV Prevention Programs to Urban Youth
COMPLETED · Phase 3
-
Effects of Biktarvy on CFR in Stable HIV Patients
COMPLETED · Phase 3
-
Reducing Sexual Risk Behaviors and Improving Health for People at a Sexually Transmitted Infection Clinic
COMPLETED · Phase 3
-
Changes in Lipids and Safety of Raltegravir in HIV+ Patients With Hyperlipidemia While on Current Standard Therapy
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.